A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-20

Study Completion Date

2018-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the effects of repeat dosing of ibrutinib on the single-dose pharmacokinetics (PK) of oral contraceptives (OC - ethinylestradiol \[EE\] and levonorgestrel \[LN\]), the cytochrome P450 (CYP)2B6 probe bupropion and the CYP3A4 probe midazolam; and to evaluate the effects of single-dose ibrutinib on the single-dose PK of the CYP3A4 probe midazolam in female participants with B cell malignancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy

NCT02381080

B-Cell Chronic Lymphocytic Leukemia

COMPLETED PHASE1

A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

NCT05963074

Leukemia, Lymphocytic, Chronic, B-Cell Small Lymphocytic Lymphoma

RECRUITING PHASE2

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

NCT02351037

Acute Myeloid Leukemia (AML)

TERMINATED PHASE2

Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

NCT03267186

Acute Biphenotypic Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia +2 more

COMPLETED PHASE2

MEOI and HRQoL in CLL Patients Treated With BTKis

NCT04938141

Chronic Lymphocytic Leukemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multicenter study of ibrutinib (first-in-class, potent, covalently-binding inhibitor of Bruton's tyrosine kinase \[BTK\]) in female participants with B cell malignancy. The study consists of 3 phases: Screening Phase (up to 28 days), 7-day Pretreatment Phase (Days 1 to 7), Treatment Phase including PK assessment period (Days 8 to 26) and a Follow-up Phase (Day 27 to end of Cycle 6). The study procedures includes electrocardiogram (ECG), vital signs, blood samples withdrawal to evaluate PK and safety. The Antitumor activity will be assessed by means of computed tomography (CT) imaging and positron emission tomography (PET) scans. No formal statistical hypothesis will be tested. This is an estimation study designed to determine if an increase or decrease in exposure to OC or probe drugs occurs in the presence of ibrutinib.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Lymphocytic, Chronic, B-Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ibrutinib + Oral Contraceptives + Probe Drugs (CYP)

Pre-treatment Phase: Participants will receive a single dose of oral contraceptive (OC) consisting of ethinylestradiol (EE) 30 microgram (mcg) and levonorgestrel (LN) 150 mcg on Study Day 1, and probe drugs (CYP) consisting of bupropion 75 milligram (mg) and midazolam 2 mg on Study Day 3, followed by a washout period from Study Days 4 to 7. Treatment Phase: Participants will receive ibrutinib 560 mg (4\*140 mg capsules) once daily (QD) on Days 8 to 26 along with midazolam 2 mg once orally on Study Day 8 (Cycle 1 Day 1), OC once orally on Study Day 22 (Cycle 1 Day 15; EE and LN), and bupropion 75 mg and midazolam 2 mg once orally on Study Day 24 (Cycle 1 Day 17). From Study Day 27 (Cycle 1 Day 20) and onwards participants will continue oral treatment with ibrutinib 420 mg (3\*140 mg capsules) or 560 mg QD (depending on the subtype of B-cell malignancy) up to the end of Cycle 6 (each cycle will consist of 28 days).

Group Type EXPERIMENTAL

Ibrutinib

Intervention Type DRUG

Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.

OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg

Intervention Type DRUG

Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.

Bupropion

Intervention Type DRUG

Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.

Midazolam

Intervention Type DRUG

Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ibrutinib

Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.

Intervention Type DRUG

OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg

Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.

Intervention Type DRUG

Bupropion

Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.

Intervention Type DRUG

Midazolam

Midazolam 2 mg (1 milliliter \[mL\]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Imbruvica Microgynon 30

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), or Waldenstrom's macroglobulinemia (WM)

1. Participants with MCL must have relapsed or refractory disease after at least 1 prior line of systemic therapy
2. Participants with MZL must have failed an anti-cluster of differentiation (CD)20 monoclonal antibody-based therapy
* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
* Adequate hematologic, hepatic, and renal functions
* Before the first dose of oral contraceptive (OC), a woman must be either:

1. Not of childbearing potential: postmenopausal (greater than \[\>\]45 years of age with amenorrhea for at least 12 months and a serum follicle stimulating hormone level \>40 international unit per Liter \[IU/L\] or milli international unit per milli Liter \[mIU/mL\]); permanently sterilized
2. Of childbearing potential and practicing a highly effective non-hormonal method of birth control
* Women of childbearing potential must have a negative serum (Beta-human chorionic gonadotropin \[Beta-hCG\]) or urine pregnancy test at screening

Exclusion Criteria

* Major surgery planned within 2 weeks of the first dose of ibrutinib or during study participation up to Cycle 2 Day 1
* History of other malignancies, except:

1. Malignancy treated with curative intent and with no known active disease present for greater than or equal to (\>=)3 years before the first dose of ibrutinib and felt to be at low risk for recurrence by treating physician
2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
3. Adequately treated in-situ cancer without evidence of disease
* History of breast or endometrial cancer
* Prior treatment/exposure with ibrutinib or other Bruton's tyrosine kinase (BTK) inhibitor
* Requires ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (for example, phenprocoumon)
* Requires therapies that must be discontinued or substituted 7 days prior to Study Day 1, or must be temporally interrupted during the course of the study, including the following:

1. Medications known to induce or inhibit drug metabolizing enzymes (CYP3A4 and CYP2B6)
2. Medication which are not allowed to be used in combination with EE, LN, bupropion, or midazolam

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No